Archive


Category: BerGenBio

  • Genmab axes development of AXL-targeting cancer drug enapotamab vedotin

    Genmab has axed development of its pipeline cancer drug enapotamab vedotin after it failed to show enough activity in a proof-of-concept trial. The drug is an antibody-drug conjugate where a monoclonal antibody is linked to monomethyl auristatin, a cancer-killing “payload”. It is targeted against AXL, a signalling molecule that is overexpressed in several haematologic and […]